CellerateRX Commences Direct-To-Consumer Sales Program via TV Spots; Positive Revenue Impact in 2011 Expected
FORT WORTH, Texas, March 10, 2011 /PRNewswire/ — Wound Management Technologies, Inc., (Pink Sheets: WNDM) a leader in advanced wound care solutions, today announced the commencement of its direct-to-consumer television sales program for CellerateRXÃ‚®, its activated collagen wound care product. TV Goods produced the commercial spot and the program is being distributed by MED3TV, LLC.
According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, “The commencement of the Direct Response sales channel is a win-win for the Company. The consumer market is a new source of revenue that will positively impact our bottom-line in fiscal 2011 and beyond. Additionally, this program will further increase our brand recognition, thus benefiting sales and the overall adoption of our other formulations sold in the ‘professional market’.”
Kevin Harrington, Chairman of H&H Imports Inc. (OTC Bulletin Board: HNHI), the parent company of TV Goods states, “We’re excited to be behind a product that we think will have mass market appeal.” Harrington is widely acknowledged as the pioneer and principal architect of the “infomercial” industry. Harrington has financed more than 500 product launches resulting in sales of more than $4 billion worldwide with 20 products reaching individual sales of over $100 million each. Steve Rogai, CEO of H&H Imports added, “The medical category is growing in the direct response industry, and I feel this product can be a definite success.”
Scott Haire, CEO of Wound Management Technologies noted, “Direct-To-Consumer sales will expand the Company’s presence throughout the industry and increase awareness of the Company and our products. We are a fast growing and innovative healthcare company made up of a driven team of seasoned industry professionals that is beginning to be discovered.”
Ronald Mathis, Wound Care Innovations’ Senior Vice President of Marketing and Sales added, “I am confident about how this sales program will be received. The show has a superior production value thanks to the skilled folks at TV Goods. We are excited about our deal with MED3TV, LLC, who will distribute the program to the various major television markets in the U.S.”
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented activated collagen product, CellerateRXÃ‚®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.
About TV Goods Holding Corporation
TV Goods is a Florida corporation located in Clearwater, Florida which develops, markets and distributes products and services primarily through infomercials and other direct response channels of distribution. TV Goods intends to leverage the experience and current high profile of its chairman, Kevin Harrington, and his management team to develop and launch marketing campaigns for a portfolio of products and services. Mr. Harrington has most recently appeared as one of the stars on ABC’s reality TV show “Shark Tank”.
About H&H Imports, Inc.
H&H is subject to the reporting requirements of the Securities and Exchange Commission and its common stock is quoted on the Over-the-Counter Bulletin Board (OTC Bulletin Board: HNHI). H&H was organized under the laws of the state of Florida to purchase and sell at wholesale women’s handbags and other leather products recently introduced products into the marketplace.
SAFE HARBOR STATEMENT:
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information: Shareholder Relations-Communications (917) 974-9872
SOURCE Wound Management Technologies, Inc.